Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 31, 2025
Product Development
Precision neuropsychiatry spotlight: a BioCentury podcast
Plus: Insights from Icon’s Peter Schueler on the ECNP Roadmap Meeting on Precision Psychiatry
BioCentury | Jan 13, 2025
Deals
Seeing high potential for antipsychotic, J&J buys Intra-Cellular for $14.6B
Continued appetite for neuroscience assets drives deal; pharma rebuilding in an area where it has become less reliant in recent years
BioCentury | Jan 7, 2025
Product Development
Biotech in the New Year. Plus: Beyond Biosecure
Picks, perils and predictions for biopharma in 2025 — the latest BioCentury podcast
BioCentury | Jan 2, 2025
Product Development
Neumora’s prospects dim for κ-opioid program after first Phase III readout
Two more studies of navacaprant underway as company considers possible female-only effect
BioCentury | Nov 11, 2024
Product Development
AbbVie’s schizophrenia miss: implications for itself, BMS and M4 pipeline
Price tag of AbbVie’s Cerevel deal now harder to justify, as BMS’s first-mover advantage extends and M4 PAMs come into question
BioCentury | Nov 6, 2024
Product Development
Two upcoming readouts could shape the market for κ-opioid antidepressants
Emerging class could find niche among patients whose major depressive disorder includes symptoms of anhedonia
BioCentury | May 30, 2024
Product Development
Clinical Report: Phase III win for J&J in neuropsychiatry; Biohaven falls on BHV-1300 data
Plus: Insmed gets boost from bronchiectasis readout and updates from HI-Bio, Corcept, Tango and Ikena
BioCentury | Jan 31, 2024
Product Development
The path to precision neuropsychiatry: J&J’s perspective
From subjective symptoms to objective metrics to biological signatures, neuroscience head Bill Martin paints a trajectory of psychiatry’s path ahead
BioCentury | Dec 21, 2023
Product Development
Diamonds in a rough 2023, predictions for 2024
BioCentury’s analysts look back at a year when innovation was hot but markets were not, and predict what’ll make news in 2024
BioCentury | Sep 15, 2023
Finance
Friday IPOs: Warm reception for RayzeBio as Neumora sags in first-day trading
As a pair of biotechs raise a combined $540M in NASDAQ offerings, how have other listings in the sector fared in the aftermarket this year?
Items per page:
1 - 10 of 174